NIDA Clinical Trials Network: Big South/West Node

NIDA 临床试验网络：大南/西节点

• 批准号: 10057104
• 负责人: Jennifer Sharpe Potter
• 金额: $ 439.8万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10057104
• 关键词: AIDS prevention; Academy; Address; African American; Alcohol or Other Drugs use; American; American Indians; Ancillary Study; Area; Arkansas; Buprenorphine; Bupropion; California; Caring; Cause of Death; Clinical; Clinical Treatment; Clinical Trials Network; Collaborations; Communities; Databases; Development; Disease; Doctor of Philosophy; Dose; Drug abuse; Drug usage; Electronic Health Record; Ethnic group; Evidence based practice; Family Physicians; Foundations; Funding; Geographic Locations; Geography; Goals; HIV; HIV Seropositivity; HIV/HCV; Health; Health Sciences; Healthcare Systems; Hepatitis C virus; Hispanics; Immigrant; Informatics; Infrastructure; International; Lead; Leadership; Length of Stay; Los Angeles; Louisiana; Measurement; Medical center; Mentors; Methamphetamine; Mission; Modeling; Multi-Institutional Clinical Trial; NCI Scholars Program; Naltrexone; Names; National Institute of Drug Abuse; Native Americans; Oklahoma; Opioid; Patient Discharge; Peer Review; Persons; Pharmacotherapy; Population; Prevention; Primary Health Care; Productivity; Public Health; Publications; Publishing; Race; Recovery; Research; Research Design; Research Personnel; Resources; Risk; Rural; Science; Scientist; Senior Scientist; Site; Solid; Substance Use Disorder; Testing; Texas; Training; Transcranial magnetic stimulation; Translational Research; Underinsured; Universities; Workforce Development; addiction; base; clinical care; cohort; combat; comorbidity; design; experience; health care settings; hospital readmission; implementation science; improved; indexing; innovation; medically underserved population; methamphetamine use; metropolitan; multi-site trial; next generation; novel; opioid epidemic; opioid use disorder; patient population; programs; racial diversity; readmission risk; response; rural setting; rural underserved; screening; stimulant use; stimulant use disorder; substance misuse; therapy development; urban setting

ABSTRACT The Big South/West Node of the NIDA Clinical Trials Network (CTN) represents an expansion of the Texas Node that has been a part of the CTN since 2005. With this expansion, the node will now be guided by the shared leadership of Madhukar H. Trivedi, MD of University of Texas Southwestern Medical Center (UTSW) Steven Shoptaw, PhD of UCLA, and Jennifer S. Potter, PhD, MPH, of UT Health Science Center at San Antonio (UTHSCSA). This fourth competing renewal application builds on our successful track record of leading CTN trials, being good network partners by providing excellent sites for multi-site studies, high productivity in publishing, and training the next generation of scientists. During the 2015-2020 funding cycle, our team developed and led: the largest pharmacotherapy trial for the treatment of methamphetamine use disorder to date (extended-release naltrexone plus high-dose bupropion; CTN0068 ADAPT-2), an in-depth study of the causes of death in a cohort of people living with HIV/HCV and substance use disorder (CTN0064A1), and an implementation study to develop and deploy universal screening for opioid use disorder and measurement based care using buprenorphine (CTN0090 MBC4OUD). Finally, a study testing transcranial magnetic stimulation (TMS) as a treatment for stimulant use disorder has been approved for development, in collaboration with the Southern Consortium Node (CTN0108). For this renewal application, we capitalize on the experience of the Multiple PIs, who collectively have expertise in the treatment of stimulants, the treatment of and public health response to the opioid crisis, and the treatment and care of HIV. Additional investigators bring content expertise spanning addiction science and clinical care, translational science, dissemination and implementation science, informatics, and trial implementation. The expanded Big South/West Node is named to denote the importance of including geographic regions in the South that have historically not been represented within the CTN (i.e., Arkansas, Oklahoma, Louisiana). This geographical expansion provides greater access to diverse patient populations (e.g., diverse racial and ethnic groups; underinsured; underserved; native [American Indian] and immigrant groups) within diverse settings (e.g., rural, urban). Our existing partnerships with primary care networks, large health care systems, and use of electronic health records (EHR) to positively impact substance use, has been further broadened to include multiple statewide networks and resources in new partner states. Our research agenda includes a focus on the fourth wave of the opioid epidemic, building upon the expertise of our investigators in treating stimulant and opioid use disorders, and the changing needs of the regions we serve. Our team has experience with innovative study designs that target all areas of the translational science continuum, and equip our Node to successfully and significantly improve the care of persons who misuse substances.

摘要 NIDA临床试验网络(CTN)的大南/西节点代表着德克萨斯州的扩展 该节点自2005年以来一直是CTN的一部分。通过此扩展，节点现在将由 德克萨斯大学西南医学中心医学博士Madhukar H.Trivedi的共同领导 加州大学洛杉矶分校博士Steven Shoptaw和加州大学旧金山分校健康科学中心公共卫生硕士Jennifer S.Potter 安东尼奥(UTHSCSA)。这第四个竞争续订申请建立在我们成功的 领导CTN试验，通过提供优秀的多站点研究网站成为良好的网络合作伙伴，高 提高出版效率，培养下一代科学家。在2015-2020年供资周期期间， 我们的团队开发并领导了：治疗甲基苯丙胺使用的最大药物疗法试验 迄今为止的障碍(缓释纳曲酮加大剂量安非他酮；CTN0068 Adapt-2)，深入 HIV/丙型肝炎病毒感染者和药物使用障碍人群死亡原因的研究 (CTN0064A1)，以及开发和部署阿片类药物使用障碍普遍筛查的实施研究 和使用丁丙诺啡(CTN0090 MBC4OUD)的基于测量的护理。最后，一项研究测试了经颅 磁刺激(TMS)作为一种治疗兴奋剂使用障碍的方法已被批准开发，在 与南方联盟节点合作(CTN0108)。对于此次续期申请，我们利用 多名PI的经验，他们共同拥有兴奋剂治疗方面的专业知识，治疗 以及对阿片类药物危机的公共卫生反应，以及艾滋病毒的治疗和护理。增加调查人员 提供内容专业知识，涵盖成瘾科学和临床护理、翻译科学、传播和 实施科学、信息学和试行。扩展的大南/西节点被命名为 以表示将历史上没有过的南方地理区域包括在内的重要性 在CTN内的代表(即阿肯色州、俄克拉何马州、路易斯安那州)。这种地域扩张提供了 更多地接触到不同的患者群体(例如，不同的种族和民族；保险不足； 服务不足；土著[美国印第安人]和移民群体)在不同的环境中(例如，农村、城市)。我们的 与初级保健网络、大型保健系统和使用电子保健的现有伙伴关系 积极影响物质使用的记录(EHR)已进一步扩大，包括全州范围内的多个 新伙伴国家的网络和资源。我们的研究议程包括关注第四波 阿片类药物流行，以我们的研究人员在治疗兴奋剂和阿片类药物使用障碍方面的专业知识为基础， 以及我们所服务地区不断变化的需求。我们的团队在创新研究设计方面拥有经验 瞄准翻译科学连续体的所有领域，并为我们的节点成功和显著 改善对滥用药物者的护理。